Toll Free: 1-888-928-9744
Toll Free: 1-888-928-9744
Published: Jan, 2015 | Pages:
61 | Publisher: Global Markets Direct
Industry: Pharmaceuticals & Healthcare | Report Format: Electronic (PDF)
Nerve Injury - Pipeline Review, H1 2015 Summary Global Markets Direct's, 'Nerve Injury - Pipeline Review, H1 2015', provides an overview of the Nerve Injury's therapeutic pipeline. This report provides comprehensive information on the therapeutic development for Nerve Injury, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Nerve Injury and special features on late-stage and discontinued projects. Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct's team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease. Scope - The report provides a snapshot of the global therapeutic landscape of Nerve Injury - The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities - The report reviews key players involved in the therapeutics development for Nerve Injury and enlists all their major and minor projects - The report summarizes all the dormant and discontinued pipeline projects - A review of the Nerve Injury products under development by companies and universities/research institutes based on information derived from company and industry-specific sources - Pipeline products coverage based on various stages of development ranging from pre-registration till discovery and undisclosed stages - A detailed assessment of monotherapy and combination therapy pipeline projects - Coverage of the Nerve Injury pipeline on the basis of target, MoA, route of administration and molecule type - Latest news and deals relating related to pipeline products Reasons to buy - Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies - Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage - Develop strategic initiatives by understanding the focus areas of leading companies - Identify and understand important and diverse types of therapeutics under development for Nerve Injury - Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline - Devise corrective measures for pipeline projects by understanding Nerve Injury pipeline depth and focus of Indication therapeutics - Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope - Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline
Table of Contents Table of Contents 2 List of Tables 4 List of Figures 5 Introduction 6 Global Markets Direct Report Coverage 6 Nerve Injury Overview 7 Therapeutics Development 8 Pipeline Products for Nerve Injury - Overview 8 Pipeline Products for Nerve Injury - Comparative Analysis 9 Nerve Injury - Therapeutics under Development by Companies 10 Nerve Injury - Therapeutics under Investigation by Universities/Institutes 11 Nerve Injury - Pipeline Products Glance 12 Clinical Stage Products 12 Early Stage Products 13 Nerve Injury - Products under Development by Companies 14 Nerve Injury - Products under Investigation by Universities/Institutes 15 Nerve Injury - Companies Involved in Therapeutics Development 16 Acorda Therapeutics, Inc. 16 Calico LLC 17 Convergence Pharmaceuticals Ltd. 18 F. Hoffmann-La Roche Ltd. 19 Kolon Life Science, Inc. 20 Medtronic, Inc. 21 Neuralstem, Inc. 22 Neurotune AG 23 Pfizer Inc. 24 Nerve Injury - Therapeutics Assessment 25 Assessment by Monotherapy Products 25 Assessment by Target 26 Assessment by Mechanism of Action 28 Assessment by Route of Administration 30 Assessment by Molecule Type 32 Drug Profiles 34 3K3A-APC - Drug Profile 34 Product Description 34 Mechanism of Action 34 R&D Progress 34 cimaglermin alfa - Drug Profile 36 Product Description 36 Mechanism of Action 36 R&D Progress 36 CLP-257 - Drug Profile 38 Product Description 38 Mechanism of Action 38 R&D Progress 38 CNV-1014802 - Drug Profile 39 Product Description 39 Mechanism of Action 39 R&D Progress 39 KLS-Nst - Drug Profile 41 Product Description 41 Mechanism of Action 41 R&D Progress 41 MDT-15 - Drug Profile 42 Product Description 42 Mechanism of Action 42 R&D Progress 42 NSI-566 - Drug Profile 43 Product Description 43 Mechanism of Action 43 R&D Progress 43 NT-1654 - Drug Profile 45 Product Description 45 Mechanism of Action 45 R&D Progress 45 Small Molecules to Activate NAMPT for Neurological Disorders - Drug Profile 46 Product Description 46 Mechanism of Action 46 R&D Progress 46 Synthetic Peptides to Inhibit PDE-4A4 for Pulmonary Fibrosis and Nerve Injury - Drug Profile 47 Product Description 47 Mechanism of Action 47 R&D Progress 47 WAY-258131 - Drug Profile 48 Product Description 48 Mechanism of Action 48 R&D Progress 48 Nerve Injury - Recent Pipeline Updates 49 Nerve Injury - Dormant Projects 58 Nerve Injury - Discontinued Products 59 Appendix 60 Methodology 60 Coverage 60 Secondary Research 60 Primary Research 60 Expert Panel Validation 60 Contact Us 61 Disclaimer 61
List of Tables Number of Products under Development for Nerve Injury, H1 2015 8 Number of Products under Development for Nerve Injury - Comparative Analysis, H1 2015 9 Number of Products under Development by Companies, H1 2015 10 Number of Products under Investigation by Universities/Institutes, H1 2015 11 Comparative Analysis by Clinical Stage Development, H1 2015 12 Comparative Analysis by Early Stage Development, H1 2015 13 Products under Development by Companies, H1 2015 14 Products under Investigation by Universities/Institutes, H1 2015 15 Nerve Injury - Pipeline by Acorda Therapeutics, Inc., H1 2015 16 Nerve Injury - Pipeline by Calico LLC, H1 2015 17 Nerve Injury - Pipeline by Convergence Pharmaceuticals Ltd., H1 2015 18 Nerve Injury - Pipeline by F. Hoffmann-La Roche Ltd., H1 2015 19 Nerve Injury - Pipeline by Kolon Life Science, Inc., H1 2015 20 Nerve Injury - Pipeline by Medtronic, Inc., H1 2015 21 Nerve Injury - Pipeline by Neuralstem, Inc., H1 2015 22 Nerve Injury - Pipeline by Neurotune AG, H1 2015 23 Nerve Injury - Pipeline by Pfizer Inc., H1 2015 24 Assessment by Monotherapy Products, H1 2015 25 Number of Products by Stage and Target, H1 2015 27 Number of Products by Stage and Mechanism of Action, H1 2015 29 Number of Products by Stage and Route of Administration, H1 2015 31 Number of Products by Stage and Molecule Type, H1 2015 33 Nerve Injury Therapeutics - Recent Pipeline Updates, H1 2015 49 Nerve Injury - Dormant Projects, H1 2015 58 Nerve Injury - Discontinued Products, H1 2015 59
Speak to the report author to design an exclusive study to serve your research needs.
Your personal and confidential information is safe and secure.
